51 /100
HIGH RISK
Score updated May 30, 2026

KYTX — Kyverna Therapeutics, Inc. Dilution Risk Tracker

Track KYTX dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track KYTX — Get alerts when the score changes →

📊 Score Breakdown

📋 Offering Ability
85
💰 Cash Runway
10
📊 Float Risk
45
⚠️ Warrant Exposure
15
🔄Convertible Debt

🌦️ Dilution Forecast

🌥️
Advisory
Moderate dilution signals present
31%
📉 Score Deterioration 40%
• Score rose 27 points recently (worsening)
💰 Capital Raise 38%
• Active shelf registration ($300M, 58% of market cap)
• Active ATM program with $100M remaining capacity
🔔 Track KYTX — Get forecast alerts →

💹 Market Data

Market Cap$517.98M
Shares Outstanding60.80M
Float35.50M
Cash$236.45M
Debt$33.76M
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 49.6% shares (2025Q4 vs prior)
101 institutional holders · 34.52M shares
#1 GordonMD Global Investments LP 4.39M shares
#2 GILEAD SCIENCES, INC. 4.13M shares
#3 Bain Capital Life Sciences Investors, LLC 3.11M shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest5.28M
Days to Cover6.2
% of Float14.9%
FINRA data as of May 15, 2026

📁 Recent SEC Activity

xbrl XBRL CONVERTIBLE Dec 31, 2024
EFFECT EFFECT Apr 02, 2026
424B5 ATM Apr 02, 2026
S-3 SHELF Mar 26, 2026
4 INSIDER TRANSACTION Mar 17, 2026
Full SEC filing analysis available with free account

📰 Recent News

No recent news
Track KYTX Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking KYTX — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required
🔬 More Research for KYTX
📊 KYTX FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 KYTX Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.